Castleman's disease: 2 Distinct clinico-pathological entities;De ziekte van Castleman: Twee afzonderlijke ziekte-entiteiten

Tijdschrift voor Geneeskunde

Volumn 60, Issue 13, 2004, Pages 949-956

  Sagaert, X ^a   De Wolf Peeters, C ^a  

^a UNIVERSITY OF LEUVEN   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

HYALIN; INTERLEUKIN 6;

AGE; ANGIOFOLLICULAR LYMPH NODE HYPERPLASIA; CAPILLARY PROLIFERATION; CLINICAL FEATURE; CYTOKINE PRODUCTION; DISEASE CLASSIFICATION; GERMINAL CENTER; HISTOPATHOLOGY; HUMAN; HUMAN HERPESVIRUS 8; KAPOSI SARCOMA; LYMPHOMA; MEDIASTINUM LYMPH NODE; PATHOGENESIS; PLASMA CELL; PROGNOSIS; REVIEW; RISK FACTOR; SYMPTOM; VIRUS INFECTION;

EID: 3142720282     PISSN: 0371683X     EISSN: None     Source Type: Journal    
DOI: 10.2143/TVG.60.13.1001911     Document Type: Review

References (23)

1. CASTLEMAN B, IVERSON L, MENENDEZ VP. Localized mediastinal lymph-node hyperplasia resembling thymoma. Cancer 1956; 9: 822-830.
2. FLENDRIG JA, SCHILLINGS PH. Benign giant lymphoma: the clinical signs and symptoms. Folia Med Neerl 1969; 12: 119-120.
3. KELLER AR, HOCHHOLZER L, CASTLEMAN B. Hyaline-vascular and plasma cell types of giant lymph node hyperplasia of the mediastinum and other locations. Cancer 1972; 39: 670-683.
4. LEIBETSEDER F, THURNER J. Angiofollikulare Lymphknotenhyperplasie (Zwiebelschalenlymphom). Med Klin 1973; 68: 817-820.
5. GABA AR, STEIN RS, SWEET DL, VARIAKOJIS D. Multicentric giant lymph node hyperplasia. Am J Clin Pathol 1978; 69: 86-90.
6. FRIZZERA G. Atypical lymphoproliferative disorders. In: Knowles MD. Neoplastic hematopathology. Philadelphia: Lippincott Williams & Wilkins, 2001: 569-622.
7. YOSHIZAKI K, MATSUDA T, NISHIMOTO N, et al. Pathogenic significance of interleukin-6 (IL-6/BSF-2) in Castleman's disease. Blood 1989; 74: 1360-1367.
8. HSU SM, WALDRON JA, XIE SS, BARLOGIE B. Expression of interleukin-6 in Castleman's disease. Hum Pathol 1993; 24: 833-839.
9. BRANDT SJ, BODINE DM, DUNBAR CE, NIENHUIS AW. Dysregulated interleukin-6 expression produces a syndrome resembling Castleman's disease in mice. J Clin Invest 1990; 86: 592-599.
10. NISHIMOTO N, SASAI M, SHIMA Y, et al. Improvement in Castleman's disease by humanized anti-interleukin-6 receptor antibody therapy. Blood 2000; 95: 56-61.
11. SOULIER J, GROLLET L, OKSENHENDLER E, et al. Kaposi's sarcoma-associated herpesvirus-like DNA sequences in multicentric Castleman's disease. Blood 1995; 86: 1276-1280.
12. MOORE PS, BOSHOFF C, WEISS RA, CHANG Y. Molecular mimicry of human cytokine and cytokine response pathway genes by KSHV. Science 1996; 274: 1739-1744.
13. PARRAVICINI C, CORBELLINO M, PAULLI M, et al. Expression of a virus-derived cytokine, KSHV vIL-6, in HIV-seronegative Castleman's disease. Am J Pathol 1997; 151: 1517-1522.
14. LARROCHE C, CACOUB P, SOULIER J, et al. Castleman's disease and lymphoma: report of eight cases in HIV-negative patients and literature review. Am J Hematol 2002; 69: 119-126.
15. HESHAM M, MEDEIROS J, MANNING J, JONES D. Dissolution of the lymphoid follicle is a feature the HHV8 + variant of plasma cell Castleman's disease. Am J Surg Pathol 2003; 27: 91-100.
16. RASASZKIEWICZ T, HANSMANN ML, LENNERT K. Monoclonality and polyclonality of plasma cells in Castleman's disease of the plasma cell variant. Histopathology 1989; 14: 11-24.
17. GHERARDI RK, MALAPERT D, DEGOS JD. Castleman's disease - POEMS syndrome overlap (letter; comment). Ann Intern Med 1990; 113: 362-367.
18. BOWNE WB, LEWIS JJ, FILIPPA DA, et al. The management of unicentric and multicentric Castleman's disease: a report of 16 cases and a review of the literature. Cancer 1999; 85: 706-717.
19. SHAHIDI H, MYERS JL. Castleman's disease. Mayo Clin Proc 1995; 70: 969-977.
20. WEISENBURGER DD, NATHWANI BN, WINBERG CD, RAPPAPORT H. Multicentric angiofollicular lymph node hyperplasia: a clinicopathologic study of 16 cases. Hum Pathol 1985; 16: 162-172.
21. PETERSON B, FRIZZERA G. Multicentric Castleman's disease. Semin Oncol 1993; 20: 636-647.
22. LEE FC, MERCHANT SH. Alleviation of systemic manifestations of multicentric Castleman's disease by thalidomide. Am J Haematol 2003; 73: 48-53.
23. NEYTS J, DE CLERCQ E. Antiviral drug susceptibility of herpesvirus. Antimicrob Agents Chemother 1997; 41: 2754-2756.